<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In intestinal epithelium, tyrosine kinase receptor Ephrin B3 (Eph B3) maintains the architecture of the crypt-villus axis by repulsive interaction with its ligand ephrin-B1 </plain></SENT>
<SENT sid="1" pm="."><plain>While loss of Eph B3 is linked to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> initiation, overexpression of Eph B3 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines inhibits growth and induces functional changes with decreased mesenchymal and increased epithelial markers </plain></SENT>
<SENT sid="2" pm="."><plain>In order to study this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor activity of Eph B3 in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> we analyzed the simultaneous expression of Eph B3 and E-cadherin in both the healthy esophagus and in Barrett's <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Simultaneous expression of Eph B3 and E-cadherin was investigated in samples from 141 patients with Barrett's <z:mp ids='MP_0002038'>carcinoma</z:mp> and from 20 healthy esophagi using immunhistology and quantitative PCR </plain></SENT>
<SENT sid="4" pm="."><plain>Results from healthy squamous <z:e sem="disease" ids="C1258085" disease_type="Disease or Syndrome" abbrv="">epithelium, Barrett</z:e>'s <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and staging-specific esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were correlated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A significantly reduced E-cadherin <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression could be detected in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> compared to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>The immunhistological activity of E-cadherin and Eph B3 was reduced in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> compared to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or healthy esophageal mucosa </plain></SENT>
<SENT sid="7" pm="."><plain>The intracellular E-cadherin distribution changed significantly from the cytoplasm to the membrane, when the Eph receptor was simultaneously expressed </plain></SENT>
<SENT sid="8" pm="."><plain>Simultaneous expression of E-cadherin and Eph B3 showed a significant inverse correlation to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: We present novel evidence of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor activity of Eph B3 in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> possibly due to the impact on redistribution of cellular E-cadherin to the membrane </plain></SENT>
<SENT sid="10" pm="."><plain>Our results suggest that this effect might play a role in the <z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence, the infiltrative growth pattern and the development of <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> </plain></SENT>
</text></document>